<p>Of the vaccines against Covid-19 approved in India, Covovax would be a better booster for those who were administered Covishield jabs than another dose of the same vaccine, according to the data available presently, noted virologist Dr Shahid Jameel said.</p>.<p>Jameel, the former head of the advisory group to the Indian SARS-COV-2 Genomics Consortia (INSACOG), said there is no data for the other combinations of vaccines as of now.</p>.<p>"Data available at this time suggests that of the vaccines approved in India, Covovax would be a better booster in Covishield-vaccinated people than another dose of Covishield," he told PTI.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/national/clear-data-supporting-very-high-immune-escape-potential-of-omicron-insacog-1065892.html" target="_blank">Clear data supporting very high immune escape potential of Omicron: INSACOG</a></strong></p>.<p>Officials have, however, said the "precaution dose" will be a third dose of the same vaccine that a person has taken.</p>.<p>Covovax has been developed by US-based vaccine maker Novavax Inc. that had announced a licence agreement with the Serum Institute of India (SII) for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in low and middle-income countries and in India.</p>.<p>The central drug authority, CDSCO, approved Covovax on Monday.</p>.<p>India is gearing up to tackle a possible third wave of the coronavirus pandemic as the Omicron variant of the virus, which is said to be much more infectious than the other strains of Covid-19, has surfaced.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/international/world-news-politics/acute-phase-of-covid-pandemic-could-end-in-2022-who-1065980.html" target="_blank">Acute phase of Covid pandemic could end in 2022: WHO</a></strong></p>.<p>The country has recorded 781 Omicron cases across 21 states and Union territories so far. Of the patients, 241 have either recovered or migrated, according to the Union health ministry.</p>.<p>In an interview to news portal "The Wire", noted virologist Gagandeep Kang said there is presently no data in India regarding which vaccine should be used for the third dose.</p>.<p>However, she cited a UK study that gauged the immune response generated in individuals who have already received two doses of the AstraZeneca (Covishield) vaccine by either a booster dose of the same vaccine or one of the Novavax (known in India as Covovax) vaccine.</p>.<p>The study found that a third dose of Covishield increased the Geometric Mean Ratio (GMR) by 3.25, while a booster dose of Covovax increased the same by eight times and one of an mRNA vaccine did so by 24 times, she said.</p>.<p><strong>Watch latest videos by DH here:</strong></p>
<p>Of the vaccines against Covid-19 approved in India, Covovax would be a better booster for those who were administered Covishield jabs than another dose of the same vaccine, according to the data available presently, noted virologist Dr Shahid Jameel said.</p>.<p>Jameel, the former head of the advisory group to the Indian SARS-COV-2 Genomics Consortia (INSACOG), said there is no data for the other combinations of vaccines as of now.</p>.<p>"Data available at this time suggests that of the vaccines approved in India, Covovax would be a better booster in Covishield-vaccinated people than another dose of Covishield," he told PTI.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/national/clear-data-supporting-very-high-immune-escape-potential-of-omicron-insacog-1065892.html" target="_blank">Clear data supporting very high immune escape potential of Omicron: INSACOG</a></strong></p>.<p>Officials have, however, said the "precaution dose" will be a third dose of the same vaccine that a person has taken.</p>.<p>Covovax has been developed by US-based vaccine maker Novavax Inc. that had announced a licence agreement with the Serum Institute of India (SII) for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in low and middle-income countries and in India.</p>.<p>The central drug authority, CDSCO, approved Covovax on Monday.</p>.<p>India is gearing up to tackle a possible third wave of the coronavirus pandemic as the Omicron variant of the virus, which is said to be much more infectious than the other strains of Covid-19, has surfaced.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/international/world-news-politics/acute-phase-of-covid-pandemic-could-end-in-2022-who-1065980.html" target="_blank">Acute phase of Covid pandemic could end in 2022: WHO</a></strong></p>.<p>The country has recorded 781 Omicron cases across 21 states and Union territories so far. Of the patients, 241 have either recovered or migrated, according to the Union health ministry.</p>.<p>In an interview to news portal "The Wire", noted virologist Gagandeep Kang said there is presently no data in India regarding which vaccine should be used for the third dose.</p>.<p>However, she cited a UK study that gauged the immune response generated in individuals who have already received two doses of the AstraZeneca (Covishield) vaccine by either a booster dose of the same vaccine or one of the Novavax (known in India as Covovax) vaccine.</p>.<p>The study found that a third dose of Covishield increased the Geometric Mean Ratio (GMR) by 3.25, while a booster dose of Covovax increased the same by eight times and one of an mRNA vaccine did so by 24 times, she said.</p>.<p><strong>Watch latest videos by DH here:</strong></p>